Research Methodology

The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:

★Stage 1 SECONDARY RESEARCH

The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.

★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES

After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.

★Stage 3 ANALYSIS OF THE GATHERED DATA

The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.

★Stage 4 QUANTITATIVE DATA

The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.

★Stage 5 QUALITY CONTROL

Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.

1 Study Coverage

1.1 Antibody Drug Conjugate (ADC) Drug Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million) Introduction

1.2 Global Antibody Drug Conjugate (ADC) Drug Outlook 2017 VS 2022 VS 2028

1.2.1 Global Antibody Drug Conjugate (ADC) Drug Market Size for the Year 2017-2028

1.2.2 Global Antibody Drug Conjugate (ADC) Drug Market Size for the Year 2017-2028

1.3 Antibody Drug Conjugate (ADC) Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028

1.3.1 The Market Share of United States Antibody Drug Conjugate (ADC) Drug in Global, 2017 VS 2022 VS 2028

1.3.2 The Growth Rate of Antibody Drug Conjugate (ADC) Drug Market Size, United States VS Global, 2017 VS 2022 VS 2028

1.4 Antibody Drug Conjugate (ADC) Drug Market Dynamics

1.4.1 Antibody Drug Conjugate (ADC) Drug Industry Trends

1.4.2 Antibody Drug Conjugate (ADC) Drug Market Drivers

1.4.3 Antibody Drug Conjugate (ADC) Drug Market Challenges

1.4.4 Antibody Drug Conjugate (ADC) Drug Market Restraints

1.5 Study Objectives

1.6 Years Considered

2 Antibody Drug Conjugate (ADC) Drug by Type

2.1 Antibody Drug Conjugate (ADC) Drug Market Segment by Type

2.1.1 Mmunomedics Technology

2.1.2 Immunogen Technology

2.1.3 Seattle Genetics Technology

2.1.4 Others

2.2 Global Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017, 2022 & 2028)

2.3 Global Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2028)

2.4 United States Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017, 2022 & 2028)

2.5 United States Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2028)

3 Antibody Drug Conjugate (ADC) Drug by Application

3.1 Antibody Drug Conjugate (ADC) Drug Market Segment by Application

3.1.1 Biotechnology Companies

3.1.2 Specialized Cancer Centers

3.1.3 Biopharmaceutical Companies

3.1.4 Academic Research Institutes

3.1.5 Hospitals

3.1.6 Others

3.2 Global Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017, 2022 & 2028)

3.3 Global Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2028)

3.4 United States Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017, 2022 & 2028)

3.5 United States Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2028)

4 Global Antibody Drug Conjugate (ADC) Drug Competitor Landscape by Company

4.1 Global Antibody Drug Conjugate (ADC) Drug Market Size by Company

4.1.1 Top Global Antibody Drug Conjugate (ADC) Drug Companies Ranked by Revenue (2021)

4.1.2 Global Antibody Drug Conjugate (ADC) Drug Revenue by Player (2017-2022)

4.2 Global Antibody Drug Conjugate (ADC) Drug Concentration Ratio (CR)

4.2.1 Antibody Drug Conjugate (ADC) Drug Market Concentration Ratio (CR) (2017-2022)

4.2.2 Global Top 5 and Top 10 Largest Companies of Antibody Drug Conjugate (ADC) Drug in 2021

4.2.3 Global Antibody Drug Conjugate (ADC) Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

4.3 Global Antibody Drug Conjugate (ADC) Drug Headquarters, Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million) Type

4.3.1 Global Antibody Drug Conjugate (ADC) Drug Headquarters and Area Served

4.3.2 Global Antibody Drug Conjugate (ADC) Drug Companies Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million) Type

4.3.3 Date of International Companies Enter into Antibody Drug Conjugate (ADC) Drug Market

4.4 Companies Mergers & Acquisitions, Expansion Plans

4.5 United States Antibody Drug Conjugate (ADC) Drug Market Size by Company

4.5.1 Top Antibody Drug Conjugate (ADC) Drug Players in United States, Ranked by Revenue (2021)

4.5.2 United States Antibody Drug Conjugate (ADC) Drug Revenue by Players (2020, 2021 & 2022)

5 Global Antibody Drug Conjugate (ADC) Drug Market Size by Region

5.1 Global Antibody Drug Conjugate (ADC) Drug Market Size by Region: 2017 VS 2022 VS 2028

5.2 Global Antibody Drug Conjugate (ADC) Drug Market Size by Region (2017-2028)

5.2.1 Global Antibody Drug Conjugate (ADC) Drug Market Size by Region: 2017-2022

5.2.2 Global Antibody Drug Conjugate (ADC) Drug Market Size by Region (2023-2028)

6 Segment in Region Level & Country Level

6.1 North America

6.1.1 North America Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth 2017-2028

6.1.2 North America Antibody Drug Conjugate (ADC) Drug Market Facts & Figures by Country (2017, 2022 & 2028)

6.1.3 U.S.

6.1.4 Canada

6.2 Asia-Pacific

6.2.1 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth 2017-2028

6.2.2 Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Facts & Figures by Region (2017, 2022 & 2028)

6.2.3 China

6.2.4 Japan

6.2.5 South Korea

6.2.6 India

6.2.7 Australia

6.2.8 Taiwan

6.2.9 Indonesia

6.2.10 Thailand

6.2.11 Malaysia

6.2.12 Philippines

6.3 Europe

6.3.1 Europe Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth 2017-2028

6.3.2 Europe Antibody Drug Conjugate (ADC) Drug Market Facts & Figures by Country (2017, 2022 & 2028)

6.3.3 Germany

6.3.4 France

6.3.5 U.K.

6.3.6 Italy

6.3.7 Russia

6.4 Latin America

6.4.1 Latin America Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth 2017-2028

6.4.2 Latin America Antibody Drug Conjugate (ADC) Drug Market Facts & Figures by Country (2017, 2022 & 2028)

6.4.3 Mexico

6.4.4 Brazil

6.4.5 Argentina

6.5 Middle East and Africa

6.5.1 Middle East and Africa Antibody Drug Conjugate (ADC) Drug Market Size YoY Growth 2017-2028

6.5.2 Middle East and Africa Antibody Drug Conjugate (ADC) Drug Market Facts & Figures by Country (2017, 2022 & 2028)

6.5.3 Turkey

6.5.4 Saudi Arabia

6.5.5 UAE

7 Company Profiles

7.1 Oxford Bio Therapeutics

7.1.1 Oxford Bio Therapeutics Company Details

7.1.2 Oxford Bio Therapeutics Business Overview

7.1.3 Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction

7.1.4 Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.1.5 Oxford Bio Therapeutics Recent Development

7.2 Synthon

7.2.1 Synthon Company Details

7.2.2 Synthon Business Overview

7.2.3 Synthon Antibody Drug Conjugate (ADC) Drug Introduction

7.2.4 Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.2.5 Synthon Recent Development

7.3 Progenics Pharmaceuticals

7.3.1 Progenics Pharmaceuticals Company Details

7.3.2 Progenics Pharmaceuticals Business Overview

7.3.3 Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction

7.3.4 Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.3.5 Progenics Pharmaceuticals Recent Development

7.4 Bayer HealthCare

7.4.1 Bayer HealthCare Company Details

7.4.2 Bayer HealthCare Business Overview

7.4.3 Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Introduction

7.4.4 Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.4.5 Bayer HealthCare Recent Development

7.5 Millennium Pharmaceuticals

7.5.1 Millennium Pharmaceuticals Company Details

7.5.2 Millennium Pharmaceuticals Business Overview

7.5.3 Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Introduction

7.5.4 Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.5.5 Millennium Pharmaceuticals Recent Development

7.6 Pfizer

7.6.1 Pfizer Company Details

7.6.2 Pfizer Business Overview

7.6.3 Pfizer Antibody Drug Conjugate (ADC) Drug Introduction

7.6.4 Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.6.5 Pfizer Recent Development

7.7 Concortis Bio therapeutics

7.7.1 Concortis Bio therapeutics Company Details

7.7.2 Concortis Bio therapeutics Business Overview

7.7.3 Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Introduction

7.7.4 Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.7.5 Concortis Bio therapeutics Recent Development

7.8 Roche Holding AG

7.8.1 Roche Holding AG Company Details

7.8.2 Roche Holding AG Business Overview

7.8.3 Roche Holding AG Antibody Drug Conjugate (ADC) Drug Introduction

7.8.4 Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.8.5 Roche Holding AG Recent Development

7.9 Seattle Genetics

7.9.1 Seattle Genetics Company Details

7.9.2 Seattle Genetics Business Overview

7.9.3 Seattle Genetics Antibody Drug Conjugate (ADC) Drug Introduction

7.9.4 Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.9.5 Seattle Genetics Recent Development

7.10 Heidelberg Pharma

7.10.1 Heidelberg Pharma Company Details

7.10.2 Heidelberg Pharma Business Overview

7.10.3 Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Introduction

7.10.4 Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.10.5 Heidelberg Pharma Recent Development

7.11 Mersana Therapeutics

7.11.1 Mersana Therapeutics Company Details

7.11.2 Mersana Therapeutics Business Overview

7.11.3 Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction

7.11.4 Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.11.5 Mersana Therapeutics Recent Development

7.12 Astellas Pharma/Agensys

7.12.1 Astellas Pharma/Agensys Company Details

7.12.2 Astellas Pharma/Agensys Business Overview

7.12.3 Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Introduction

7.12.4 Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.12.5 Astellas Pharma/Agensys Recent Development

7.13 AbbVie Inc

7.13.1 AbbVie Inc Company Details

7.13.2 AbbVie Inc Business Overview

7.13.3 AbbVie Inc Antibody Drug Conjugate (ADC) Drug Introduction

7.13.4 AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.13.5 AbbVie Inc Recent Development

7.14 Celldex Therapeutics

7.14.1 Celldex Therapeutics Company Details

7.14.2 Celldex Therapeutics Business Overview

7.14.3 Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Introduction

7.14.4 Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.14.5 Celldex Therapeutics Recent Development

7.15 Immunomedics

7.15.1 Immunomedics Company Details

7.15.2 Immunomedics Business Overview

7.15.3 Immunomedics Antibody Drug Conjugate (ADC) Drug Introduction

7.15.4 Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.15.5 Immunomedics Recent Development

7.16 Agensys

7.16.1 Agensys Company Details

7.16.2 Agensys Business Overview

7.16.3 Agensys Antibody Drug Conjugate (ADC) Drug Introduction

7.16.4 Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.16.5 Agensys Recent Development

7.17 Genentech

7.17.1 Genentech Company Details

7.17.2 Genentech Business Overview

7.17.3 Genentech Antibody Drug Conjugate (ADC) Drug Introduction

7.17.4 Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.17.5 Genentech Recent Development

7.18 ImmunoGen

7.18.1 ImmunoGen Company Details

7.18.2 ImmunoGen Business Overview

7.18.3 ImmunoGen Antibody Drug Conjugate (ADC) Drug Introduction

7.18.4 ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.18.5 ImmunoGen Recent Development

7.19 Sanofi

7.19.1 Sanofi Company Details

7.19.2 Sanofi Business Overview

7.19.3 Sanofi Antibody Drug Conjugate (ADC) Drug Introduction

7.19.4 Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.19.5 Sanofi Recent Development

7.20 Genmab

7.20.1 Genmab Company Details

7.20.2 Genmab Business Overview

7.20.3 Genmab Antibody Drug Conjugate (ADC) Drug Introduction

7.20.4 Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.20.5 Genmab Recent Development

7.21 Amgen

7.21.1 Amgen Company Details

7.21.2 Amgen Business Overview

7.21.3 Amgen Antibody Drug Conjugate (ADC) Drug Introduction

7.21.4 Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.21.5 Amgen Recent Development

7.22 Novartis

7.22.1 Novartis Company Details

7.22.2 Novartis Business Overview

7.22.3 Novartis Antibody Drug Conjugate (ADC) Drug Introduction

7.22.4 Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.22.5 Novartis Recent Development

7.23 Eli Lilly

7.23.1 Eli Lilly Company Details

7.23.2 Eli Lilly Business Overview

7.23.3 Eli Lilly Antibody Drug Conjugate (ADC) Drug Introduction

7.23.4 Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

7.23.5 Eli Lilly Recent Development

8 Research Findings and Conclusion

9 Appendix

9.1 Research Methodology

9.1.1 Methodology/Research Approach

9.1.2 Data Source

9.2 Author Details

9.3 Disclaimer

List of Tables

Table 1. Antibody Drug Conjugate (ADC) Drug Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)

Table 2. Antibody Drug Conjugate (ADC) Drug Market Trends

Table 3. Antibody Drug Conjugate (ADC) Drug Market Drivers

Table 4. Antibody Drug Conjugate (ADC) Drug Market Challenges

Table 5. Antibody Drug Conjugate (ADC) Drug Market Restraints

Table 6. Global Antibody Drug Conjugate (ADC) Drug Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)

Table 7. United States Antibody Drug Conjugate (ADC) Drug Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)

Table 8. Global Antibody Drug Conjugate (ADC) Drug Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)

Table 9. United States Antibody Drug Conjugate (ADC) Drug Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)

Table 10. Top Antibody Drug Conjugate (ADC) Drug Companies in Global Market, Ranking by Revenue (2021)

Table 11. Global Antibody Drug Conjugate (ADC) Drug Revenue by Player, (US$ Million), 2017-2022

Table 12. Global Antibody Drug Conjugate (ADC) Drug Revenue Share by Player, 2017-2022

Table 13. Global Antibody Drug Conjugate (ADC) Drug Companies Market Concentration Ratio (CR5 and HHI)

Table 14. Global Antibody Drug Conjugate (ADC) Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate (ADC) Drug as of 2021)

Table 15. Top Players of Antibody Drug Conjugate (ADC) Drug in Global Market, Headquarters and Area Served

Table 16. Companies Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million) Type

Table 17. Date of International Companies Enter into Antibody Drug Conjugate (ADC) Drug Market

Table 18. Companies Mergers & Acquisitions, Expansion Plans

Table 19. Top Antibody Drug Conjugate (ADC) Drug Players in United States Market, Ranking by Revenue (2021)

Table 20. United States Antibody Drug Conjugate (ADC) Drug Revenue by Players, (US$ Million), 2020, 2021 & 2022

Table 21. United States Antibody Drug Conjugate (ADC) Drug Revenue Share by Players, 2020, 2021 & 2022

Table 22. Global Antibody Drug Conjugate (ADC) Drug Market Size by Region (US$ Million): 2017 VS 2022 VS 2028

Table 23. Global Antibody Drug Conjugate (ADC) Drug Market Size by Region (2017-2022) & (US$ Million)

Table 24. Global Antibody Drug Conjugate (ADC) Drug Market Size Forecast by Region (2023-2028) & (US$ Million)

Table 25. North America Antibody Drug Conjugate (ADC) Drug Sales in Value by Country (2017-2028) & (US$ Million)

Table 26. Asia Pacific Antibody Drug Conjugate (ADC) Drug Sales in Value by Region (2017-2028) & (US$ Million)

Table 27. Europe Antibody Drug Conjugate (ADC) Drug Sales in Value by Country (2017-2028) & (US$ Million)

Table 28. Latin Americaa Antibody Drug Conjugate (ADC) Drug Sales in Value by Country (2017-2028) & (US$ Million)

Table 29. Middle East and Africa Antibody Drug Conjugate (ADC) Drug Sales in Value by Country (2017-2028) & (US$ Million)

Table 30. Oxford Bio Therapeutics Company Details

Table 31. Oxford Bio Therapeutics Business Overview

Table 32. Oxford Bio Therapeutics Antibody Drug Conjugate (ADC) Drug Product

Table 33. Oxford Bio Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 34. Oxford Bio Therapeutics Recent Development

Table 35. Synthon Company Details

Table 36. Synthon Business Overview

Table 37. Synthon Antibody Drug Conjugate (ADC) Drug Product

Table 38. Synthon Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 39. Synthon Recent Development

Table 40. Progenics Pharmaceuticals Company Details

Table 41. Progenics Pharmaceuticals Business Overview

Table 42. Progenics Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Product

Table 43. Progenics Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 44. Progenics Pharmaceuticals Recent Development

Table 45. Bayer HealthCare Company Details

Table 46. Bayer HealthCare Business Overview

Table 47. Bayer HealthCare Antibody Drug Conjugate (ADC) Drug Product

Table 48. Bayer HealthCare Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 49. Bayer HealthCare Recent Development

Table 50. Millennium Pharmaceuticals Company Details

Table 51. Millennium Pharmaceuticals Business Overview

Table 52. Millennium Pharmaceuticals Antibody Drug Conjugate (ADC) Drug Product

Table 53. Millennium Pharmaceuticals Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 54. Millennium Pharmaceuticals Recent Development

Table 55. Pfizer Company Details

Table 56. Pfizer Business Overview

Table 57. Pfizer Antibody Drug Conjugate (ADC) Drug Product

Table 58. Pfizer Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 59. Pfizer Recent Development

Table 60. Concortis Bio therapeutics Company Details

Table 61. Concortis Bio therapeutics Business Overview

Table 62. Concortis Bio therapeutics Antibody Drug Conjugate (ADC) Drug Product

Table 63. Concortis Bio therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 64. Concortis Bio therapeutics Recent Development

Table 65. Roche Holding AG Company Details

Table 66. Roche Holding AG Business Overview

Table 67. Roche Holding AG Antibody Drug Conjugate (ADC) Drug Product

Table 68. Roche Holding AG Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 69. Roche Holding AG Recent Development

Table 70. Seattle Genetics Company Details

Table 71. Seattle Genetics Business Overview

Table 72. Seattle Genetics Antibody Drug Conjugate (ADC) Drug Product

Table 73. Seattle Genetics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 74. Seattle Genetics Recent Development

Table 75. Heidelberg Pharma Company Details

Table 76. Heidelberg Pharma Business Overview

Table 77. Heidelberg Pharma Antibody Drug Conjugate (ADC) Drug Product

Table 78. Heidelberg Pharma Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 79. Heidelberg Pharma Recent Development

Table 80. Mersana Therapeutics Company Details

Table 81. Mersana Therapeutics Business Overview

Table 82. Mersana Therapeutics Antibody Drug Conjugate (ADC) Drug Product

Table 83. Mersana Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 84. Mersana Therapeutics Recent Development

Table 85. Astellas Pharma/Agensys Company Details

Table 86. Astellas Pharma/Agensys Business Overview

Table 87. Astellas Pharma/Agensys Antibody Drug Conjugate (ADC) Drug Product

Table 88. Astellas Pharma/Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 89. Astellas Pharma/Agensys Recent Development

Table 90. AbbVie Inc Company Details

Table 91. AbbVie Inc Business Overview

Table 92. AbbVie Inc Antibody Drug Conjugate (ADC) Drug Product

Table 93. AbbVie Inc Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 94. AbbVie Inc Recent Development

Table 95. Celldex Therapeutics Company Details

Table 96. Celldex Therapeutics Business Overview

Table 97. Celldex Therapeutics Antibody Drug Conjugate (ADC) Drug Product

Table 98. Celldex Therapeutics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 99. Celldex Therapeutics Recent Development

Table 100. Immunomedics Company Details

Table 101. Immunomedics Business Overview

Table 102. Immunomedics Antibody Drug Conjugate (ADC) Drug Product

Table 103. Immunomedics Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 104. Immunomedics Recent Development

Table 105. Agensys Company Details

Table 106. Agensys Business Overview

Table 107. Agensys Antibody Drug Conjugate (ADC) Drug Product

Table 108. Agensys Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 109. Agensys Recent Development

Table 110. Genentech Company Details

Table 111. Genentech Business Overview

Table 112. Genentech Antibody Drug Conjugate (ADC) Drug Product

Table 113. Genentech Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 114. Genentech Recent Development

Table 115. ImmunoGen Company Details

Table 116. ImmunoGen Business Overview

Table 117. ImmunoGen Antibody Drug Conjugate (ADC) Drug Product

Table 118. ImmunoGen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 119. ImmunoGen Recent Development

Table 120. Sanofi Company Details

Table 121. Sanofi Business Overview

Table 122. Sanofi Antibody Drug Conjugate (ADC) Drug Product

Table 123. Sanofi Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 124. Sanofi Recent Development

Table 125. Genmab Company Details

Table 126. Genmab Business Overview

Table 127. Genmab Antibody Drug Conjugate (ADC) Drug Product

Table 128. Genmab Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 129. Genmab Recent Development

Table 130. Amgen Company Details

Table 131. Amgen Business Overview

Table 132. Amgen Antibody Drug Conjugate (ADC) Drug Product

Table 133. Amgen Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 134. Amgen Recent Development

Table 135. Novartis Company Details

Table 136. Novartis Business Overview

Table 137. Novartis Antibody Drug Conjugate (ADC) Drug Product

Table 138. Novartis Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 139. Novartis Recent Development

Table 140. Eli Lilly Company Details

Table 141. Eli Lilly Business Overview

Table 142. Eli Lilly Antibody Drug Conjugate (ADC) Drug Product

Table 143. Eli Lilly Revenue in Antibody Drug Conjugate (ADC) Drug Business (2017-2022) & (US$ Million)

Table 144. Eli Lilly Recent Development

Table 145. Research Programs/Design for This Report

Table 146. Key Data Information from Secondary Sources

Table 147. Key Data Information from Primary Sources

List of Figures

Figure 1. Antibody Drug Conjugate (ADC) Drug Product Picture

Figure 2. Global Antibody Drug Conjugate (ADC) Drug Market Size, (US$ Million), 2017 VS 2022 VS 2028

Figure 3. Global Antibody Drug Conjugate (ADC) Drug Market Size 2017-2028 (US$ Million)

Figure 4. United States Antibody Drug Conjugate (ADC) Drug Market Size, (US$ Million), 2017 VS 2022 VS 2028

Figure 5. United States Antibody Drug Conjugate (ADC) Drug Market Size 2017-2028 (US$ Million)

Figure 6. United States Antibody Drug Conjugate (ADC) Drug Market Share in Global 2017-2028

Figure 7. Antibody Drug Conjugate (ADC) Drug Report Years Considered

Figure 8. Product Picture of Mmunomedics Technology

Figure 9. Product Picture of Immunogen Technology

Figure 10. Product Picture of Seattle Genetics Technology

Figure 11. Product Picture of Others

Figure 12. Global Antibody Drug Conjugate (ADC) Drug Market Share by Type in 2022 & 2028

Figure 13. Global Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2028) & (US$ Million)

Figure 14. Global Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)

Figure 15. United States Antibody Drug Conjugate (ADC) Drug Market Share by Type in 2022 & 2028

Figure 16. United States Antibody Drug Conjugate (ADC) Drug Market Size by Type (2017-2028) & (US$ Million)

Figure 17. United States Antibody Drug Conjugate (ADC) Drug Market Share by Type (2017-2028)

Figure 18. Product Picture of Biotechnology Companies

Figure 19. Product Picture of Specialized Cancer Centers

Figure 20. Product Picture of Biopharmaceutical Companies

Figure 21. Product Picture of Academic Research Institutes

Figure 22. Product Picture of Hospitals

Figure 23. Product Picture of Others

Figure 24. Global Antibody Drug Conjugate (ADC) Drug Market Share by Application in 2022 & 2028

Figure 25. Global Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2028) & (US$ Million)

Figure 26. Global Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)

Figure 27. United States Antibody Drug Conjugate (ADC) Drug Market Share by Application in 2022 & 2028

Figure 28. United States Antibody Drug Conjugate (ADC) Drug Market Size by Application (2017-2028) & (US$ Million)

Figure 29. United States Antibody Drug Conjugate (ADC) Drug Market Share by Application (2017-2028)

Figure 30. North America Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate 2017-2028 (US$ Million)

Figure 31. U.S. Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 32. Canada Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 33. Europe Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate 2017-2028 (US$ Million)

Figure 34. Germany Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 35. France Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 36. U.K. Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 37. Italy Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 38. Russia Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 39. Asia-Pacific Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate 2017-2028 (US$ Million)

Figure 40. China Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 41. Japan Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 42. South Korea Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 43. India Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 44. Australia Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 45. Taiwan Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 46. Indonesia Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 47. Thailand Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 48. Malaysia Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 49. Philippines Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 50. Latin America Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate 2017-2028 (US$ Million)

Figure 51. Mexico Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 52. Brazil Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 53. Argentina Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 54. Middle East & Africa Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate 2017-2028 (US$ Million)

Figure 55. Turkey Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 56. Saudi Arabia Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 57. UAE Antibody Drug Conjugate (ADC) Drug Market Size Growth Rate (2017-2028) & (US$ Million)

Figure 58. Oxford Bio Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 59. Synthon Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 60. Progenics Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 61. Bayer HealthCare Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 62. Millennium Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 63. Pfizer Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 64. Concortis Bio therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 65. Roche Holding AG Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 66. Seattle Genetics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 67. Heidelberg Pharma Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 68. Mersana Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 69. Astellas Pharma/Agensys Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 70. AbbVie Inc Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 71. Celldex Therapeutics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 72. Immunomedics Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 73. Agensys Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 74. Genentech Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 75. ImmunoGen Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 76. Sanofi Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 77. Genmab Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 78. Amgen Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 79. Novartis Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 80. Eli Lilly Revenue Growth Rate in Antibody Drug Conjugate (ADC) Drug Business (2017-2022)

Figure 81. Bottom-up and Top-down Approaches for This Report

Figure 82. Data Triangulation

Figure 83. Key Executives Interviewed